FOR IMMEDIATE RELEASE Translate Bio Appoints … Sidney Street, Suite 310 Cambridge, MA 02139 P...
Transcript of FOR IMMEDIATE RELEASE Translate Bio Appoints … Sidney Street, Suite 310 Cambridge, MA 02139 P...
200 Sidney Street, Suite 310 Cambridge, MA 02139 P (617) 945 7361 FORIMMEDIATERELEASE
TranslateBioAppointsAnnBarbier,M.D.,Ph.D.,asChiefMedicalOfficer
CAMBRIDGE,Mass.–November6,2017–TranslateBio,aleadingbiotechnologycompanyfocusedonpioneeringthetranslationofRNAscienceintotherapeuticspromotinghealthygeneexpressioninpeoplelivingwithdebilitatinggeneticdiseases,todayannouncedtheappointmentofAnnBarbier,M.D.,Ph.D.,aschiefmedicalofficer,effectiveimmediately.Dr.Barbierbringsnearly20yearsofdrugdiscoveryanddevelopmentexperiencetoTranslateBio,andwillberesponsibleforleadingallclinicalresearchanddevelopment,medicalaffairsandrelatedfunctionsatTranslateBio.“WearethrilledtowelcomeDr.BarbiertoTranslateBio,”saidRonaldRenaud,chiefexecutiveofficer,TranslateBio.“Sheisaprovenleaderwithatrackrecordofadvancingclinicalresearchthroughallphasesofdevelopment.Additionally,Dr.Barbier’srarediseaseexpertiseandextensiveexperienceengagingregulatoryagenciesmakeheraninvaluableassetaswelookaheadtoinitiatingourfirstclinicalstudyincysticfibrosisinearly2018.”“Withnear-termclinicalprogramsincysticfibrosisandOTCdeficiency,TranslateBioisapproachingacriticalandexcitingtime,”saidDr.Barbier.“Ourplatformhasthepotentialtobetransformativeforpatients,andIamincrediblyexcitedabouttheopportunitytojoinanexperiencedmanagementteamdedicatedtofindinginnovativetreatmentsinareasofhighunmetneed.”PriortojoiningTranslateBio,Dr.Barbierwasvicepresidentofclinicaldevelopment,raregeneticdiseases,atAgiosPharmaceuticals,wheresheledthedevelopmentprogramofasmallmoleculeinrarebenignhematologicaldiseases.Previously,Dr.BarbierspentsevenyearsatShire,mostrecentlyasglobalclinicaldevelopmentleadandseniormedicaldirector,wheresheworkedonavarietyofraregeneticdiseasesincludinglysosomalstoragediseasesandhereditaryangioedema.HerpriorexperienceincludespositionsatEnvivo,Johnson&JohnsonandAventis.Duringhercareer,Dr.BarbierhasmadesignificantcontributionstoseveralapprovedproductssuchasElaprase(Huntersyndrome),Aubagio(multiplesclerosis)andFirazyr(hereditaryangioedema)andhasledseveralinvestigationalnewdrugapplicationsfornewchemicalentities.Additionally,shehasauthoredmorethan50peer-reviewedscientificarticles,bookchaptersandinvitedreviews.Dr.BarbierreceivedherM.D.andPh.D.inpharmacologyfromtheUniversityofGent,Belgium,andaMasterofSciencefromtheFreeUniversityofBrussels,Belgium.ShepursuedapostdoctoralfellowshipattheUniversityofTennesseeinMemphis.
200 Sidney Street, Suite 310 Cambridge, MA 02139 P (617) 945 7361 AboutTranslateBioTranslateBioisaleadingbiotechnologycompanyfocusedonpioneeringthetranslationofRNAscienceintotherapeuticspromotinghealthygeneexpressioninpeoplelivingwithdebilitatinggeneticdiseases.Thecompany’sRNAplatformsforpoweringendogenoustherapeuticproteinproductionisapplicabletoabroadrangeofdiseasescausedbyinsufficientproteinproduction,includingrarediseasesoftheliver,lungandcentralnervoussystem.Formoreinformationaboutthecompany,pleasevisitwww.translate.bio.
###
ContactforTranslateBioMauraGavaghanCorporateCommunicationsmgavaghan@translate.bio857-242-7789